Pre-check
Complete safety and eligibility questions.
Wegovy
Mounjaro
Ozempic
Assessment, prescribing when suitable and structured follow-up—without a physical clinic appointment.
The doctor chooses treatment according to the authorised indication, medical history, eligibility and response.
Semaglutide · weight management
Licensed weight-management pathway with gradual dose escalation.
Explore Wegovy →
Tirzepatide · weight management
Weekly treatment with staged dosing and clinical follow-up.
Explore Mounjaro →
Semaglutide · type 2 diabetes
Authorised for adults with type 2 diabetes—not presented as a routine weight-loss substitute.
Explore Ozempic →
The doctor reviews BMI, weight-related conditions, previous treatment, current medicines, pregnancy plans and safety exclusions.
Complete safety and eligibility questions.
Choose the €39 consultation.
Discuss history, goals and dosage.
QR e-prescription if clinically suitable.
Prepare your current weight, appetite changes, side effects and any new medicines. The aim is the lowest effective dose that supports progress with manageable side effects.
Evidence-based guidance reviewed by Dr Ben Harry Clegg, Málaga registration 292911940.
No physical appointment is normally needed, although local examination or tests may be recommended.
No. Prescription follows only when the doctor confirms clinical suitability.
Usually monthly during dose adjustment.
Nausea, diarrhoea, constipation and vomiting are commonly discussed.
Yes; bring evidence of current medicine, dose and treatment history.
Storage instructions differ by medicine and pen type.
The doctor considers indication, medical history, previous response and safety.
Ozempic is authorised in the EU for type 2 diabetes. Wegovy is the semaglutide brand authorised for weight management.
Read the complete prescription process or choose a city, island or local area for practical pharmacy, nearby-area and travel guidance.